Clinical Trials Logo

Meniere Disease clinical trials

View clinical trials related to Meniere Disease.

Filter by:

NCT ID: NCT01084525 Completed - Meniere's Disease Clinical Trials

OTO-104 for Meniere's Disease

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.

NCT ID: NCT00831688 Completed - Meniere's Disease Clinical Trials

Efficacy of Local Overpressure Treatment for Meniere's Disease

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study to date, is that no causal therapy for Meniere's disease has been discovered. Local overpressure treatment for Meniere's disease is a new treatment form that has been shown in animal and human experiments to reduce the endolymphatic hydrops, a condition that is generally believed to be the pathologic hallmark of Meniere's disease. This study analyzes the efficacy of local overpressure treatment by measuring subjective vertigo severity and objective audiovestibular function parameters.

NCT ID: NCT00802529 Completed - Meniere's Disease Clinical Trials

Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease

Start date: April 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This trial aims to compare transtympanic steroids against the standard treatment (transtympanic gentamicin) in refractory unilateral Meniere's disease.

NCT ID: NCT00599560 Completed - Meniere Disease Clinical Trials

Vasopressin and V2 Receptor in Meniere's Disease

Start date: April 1998
Phase: N/A
Study type: Interventional

Summary: Some of sicknesses are well known to be provoked by inadequate adaptation to physical and/or psychogenic stress in their daily life. Meniere's disease is also a common inner ear disease accompanied with vertigo, hearing loss and tinnitus especially in civilized people under stressed life style. Its oto-pathology was firstly revealed in 1938 to be inner ear endolymphatic hydrops through the temporal bone study. To elucidate the neuroscientific relationship between "stress" and "inner ear", we examined plasma vasopressin (the anti-diuretic "stress" hormone) and its receptor, V2R in the endolymphatic sac (the "inner ear" endo-organ for endolymph absorption) in Meniere's patients.

NCT ID: NCT00500474 Completed - Meniere's Disease Clinical Trials

Effects of Endolymphatic Sac Drainage With Steroids for Meniere’s Disease

EDSS
Start date: April 1996
Phase: N/A
Study type: Interventional

Meniere's disease is a common inner ear disease with an incidence of 15-50 per 100,000 population. Since Meniere’s disease is thought to be triggered by an immune insult to inner ear, we examined intra-endolymphatic sac application of large doses of steroids as de novo treatment for intractable Meniere’s disease.

NCT ID: NCT00160238 Completed - Meniere's Disease Clinical Trials

Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy

Start date: January 2003
Phase: Phase 4
Study type: Interventional

This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's disease.

NCT ID: NCT00145483 Completed - Meniere's Disease Clinical Trials

Sildenafil For Meniere's Disease

Start date: June 18, 2002
Phase: Phase 4
Study type: Interventional

Meniere's disease affects a person's sense of balance. An attack can last 20 minutes to 2 hours or longer. Symptoms include rotational vertigo, hearing loss, tinnitus and a sensation of fullness in the affected ear and may be associated with nausea and vomiting. One hypothesis is that Meniere's disease is caused by the excessive accumulation of fluid in the balance tubes within the inner ear. Sildenafil may alleviate the symptoms due to its vasodilatory activity. The purpose of this study is to assess the safety and efficacy of sildenafil (Viagra) compared with placebo on symptoms during one acute attack.